---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122792"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:59:06.094745+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M

## Summary
- Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.
- Cash, equivalents, and short-term investments $320.7M; expected to fund operations through end of 2026.
- RAP-219 Phase 2a focal epilepsy trial on track; topline data expected mid-2025. MAD-2 and PET results Q1 2025.
- FDA placed IND for diabetic peripheral neuropathic pain (DPNP) on clinical hold; focal epilepsy trial unaffected.
- Appointed four new board members (Rob Perez, Raymond Sanchez, Paul Silva, Wendy Young); Jeff Tong resigned.

## SEC filing metadata
- accession: 0000950170-24-122792
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/0000950170-24-122792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/rapp-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122792
- JSON: https://secwatch.observer/filing/0000950170-24-122792.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.